Fairtility, a Tel Aviv Israel-based transparent AI innovator powering in vitro fertilization (IVF), closed a $15 million Series A funding round.
The round, which brings total funding to $18.5m to date, was led by Gurnet Point Capital, and included Nacre Capital and additional investors.
The company intends to use the funds to advance clinical research with fertility clinics and academic institutions globally, regulatory approval processes, as well as to develop CHLOE™ beyond embryo assessment to span the full breadth of IVF treatment.
Led by Eran Eshed, Co-Founder and CEO, Fairtility provides an Embryo Quality Assessment Assistant that transforms AI-decision-making in IVF into a transparent process for both clinicians and patients. CHLOE EQ™ (Cultivating Human Life through Optimal Embryos) provides visibility into the biological data that informs the system’s embryo assessment conclusions. Its data output is intended to support IVF professionals’ experience and intuition, augmenting decision-making with the collective analysis of millions of data points collected from a diverse set of embryology labs and workflows globally. Powering IVF professionals with this data facilitates improved decision-making and informative conversations with patients with the goal of reducing the number of IVF cycles to live birth and improving patient care.
FinSMEs
24/05/2022